海角破解版

EasySep? Mouse CD138 Positive Selection Kit

Immunomagnetic positive selection of mouse CD138+ cells

EasySep? Mouse CD138 Positive Selection Kit

Immunomagnetic positive selection of mouse CD138+ cells

Catalog #
(Select a product)
Immunomagnetic positive selection of mouse CD138+ cells
Request Pricing Request Pricing

Product Advantages


  • Fast, easy-to-use and column-free

  • Up to 97% purity with immunized mice

  • Useful for the enrichment of plasma cells

  • Compatible with hybridoma generation protocols, including electrofusion

What's Included

  • EasySep? Mouse CD138 Positive Selection Kit (Catalog #18957)
    • EasySep? Mouse CD138 Positive Selection Cocktail, 1 mL
    • EasySep? Dextran RapidSpheres? 50100, 1 mL
    • EasySep? Mouse FcR Blocker, 2 x 0.5 mL
  • RoboSep? Mouse CD138 Positive Selection Kit (Catalog #18957RF)
    • EasySep? Mouse CD138 Positive Selection Cocktail, 1 mL
    • EasySep? Dextran RapidSpheres? 50100, 1 mL
    • EasySep? Mouse FcR Blocker, 2 x 0.5 mL
    • RoboSep? Buffer (Catalog #20104)
    • RoboSep? Filter Tips (Catalog #20125)
    • EasySep? EasyTube?-14 (Catalog #20128) x 2
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

Overview

Isolate highly purified mouse CD138+ cells from mouse splenocytes, lymph nodes, or bone marrow samples by immunomagnetic positive selection, with the EasySep? Mouse CD138 Positive Selection Kit. Widely used in published research for more than 20 years, EasySep? combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.

In this EasySep? positive selection procedure, desired cells are labeled with antibody complexes recognizing CD138 and magnetic particles. Labeled cells are separated using an EasySep? magnet and by simply pouring or pipetting off the unwanted cells. The cells of interest remain in the tube. Following magnetic cell isolation, the desired CD138+ cells are ready for downstream applications such as flow cytometry, cell culture, and hybridoma generation.

Learn more about how immunomagnetic EasySep? technology works or how to fully automate immunomagnetic cell isolation with RoboSep?. Explore additional products optimized for your workflow, including culture media, supplements, antibodies, and more.
Magnet Compatibility
? EasySep? Magnet (Catalog #18000)
? “The Big Easy” EasySep? Magnet (Catalog #18001)
? EasyEights? EasySep? Magnet (Catalog #18103)
? RoboSep?-S (Catalog #21000)
Subtype
Cell Isolation Kits
Cell Type
B Cells, Plasma
Species
Mouse
Sample Source
Bone Marrow, Lymph Node, Other, Spleen
Selection Method
Positive
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Immunology

Data Figures

Typical EasySep™ Mouse CD138 Positive Cell Isolation Profile

Figure 1. Typical EasySep™ Mouse CD138 Positive Cell Isolation Profile

(A) Starting with immunized BALB/c mouse splenocytes, the CD138+ cell content of the isolated fraction is typically 81.5 ± 4.9% (mean ± SD). In the above example, the purities of the start and final isolated fractions are 4.6% and 83.3%, respectively.

(B) Starting with immunized BALB/c mouse splenocytes, the plasma cell (CD138+CD267 (TACI)+) content is typically 68.5 ± 11.3% (mean ± SD). In the above example, the purities of the start and final isolated fractions are 1.3% and 70.2%, respectively.

(C) Starting with na?ve C57BL/6 mouse splenocytes, the CD138+ cell content of the isolated fraction is typically 78.3 ± 5.7% (mean ± SD). In the above example, the purities of the start and final isolated fractions are 5.0% and 79.5%, respectively.

(D) Starting with na?ve C57BL/6 mouse splenocytes, the plasma cell (CD138+CD267 (TACI)+) content is typically 50.8 ± 10.0 % (mean ± SD). In the above example, the purities of the start and final isolated fractions are 0.4% and 56.3%, respectively.

(E) Isolated CD138+ cells or total splenocytes from mice immunized with various antigens were fused with Sp2/0 mouse myeloma cells and plated in semi-solid medium using ClonaCell™-HY Hybridoma Kit (Catalog #03800). The % antigen-specific hit rate was determined by ELISA. The % antigen-specific hit rates for total splenocytes and CD138+ cells were 4.1 ± 1.6% and 28.8 ± 11.0% (mean ± SD), respectively.

(F) Isolated CD138+ cells or total splenocytes from mice immunized with various antigens were fused with Sp2/0 mouse myeloma cells and plated in semi-solid medium using ClonaCell™-HY Hybridoma Kit (Catalog #03800). The % antibody-secreting hybridomas was determined by ELISA. The % antibody-secreting hybridomas for total splenocytes and CD138+ cells were 33.0 ± 8.7% and 99.3 ± 0.6% (mean ± SD), respectively.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
18957
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18957RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18957
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18957
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18957
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18957RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18957RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18957RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18957RF
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (5)

A novel electric field approach for improving cognitive function through ameliorating cell-specific pathology in P301S tauopathy mice J. Zhou et al. Alzheimer's Research & Therapy 2025 Sep

Abstract

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, with no effective treatment currently available. Recently, non-pharmacological therapy, especially gamma frequency stimulation has shown promising therapeutic effects in Alzheimer’s disease (AD) mouse models. Electric field (EF) is a non-invasive biophysical approach for neuronal protection. However, whether EF is beneficial in AD neuropathology remains unknown. In this study, we exposed the P301S tauopathy mouse model to EF at gamma frequency on the head. We demonstrated that EF treatment significantly improved the cognitive impairments in the P301S mice. This was accompanied by reduced tau pathologies, suppressed microglial activation, neuroinflammation and oxidative stress in the tauopathy mouse brain. Moreover, EF treatment induced cell-specific responses in neural cells, with neurons being more susceptible, followed by microglia and oligodendrocytes. EF also had favorable effects on synaptic protein in neurons, inflammatory response and complement signaling in microglia, and myelination in oligodendrocytes. This study provides strong evidence that EF at gamma frequency may have great potential to be a novel therapeutic intervention for P301S by attenuating neuropathology and offering neuroprotection.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13195-025-01859-8.
Preclinical development of an immunoassay for the detection of TREM2: a new biomarker for Alzheimer’s disease Scientific Reports 2025 Jul

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein. The combination of biomarkers is crucial for AD diagnosis. The triggering receptor expressed on myeloid cells 2 (TREM2), a receptor expressed on microglia, is important in AD pathogenesis. Impairment of TREM2 function aggravates the toxic effects of amyloid plaques, and its activation has been shown to reduce Aβ burden and memory deficits. Increased levels of soluble TREM2 (sTREM2) in blood and cerebrospinal fluid is associated with AD. Therefore, TREM2 could serve as a non-invasive biomarker for AD. In this study, we developed a preclinical immunoassay to detect TREM2 for AD diagnosis. Highly sensitive and specific TREM2 antibodies were produced using the hybridoma technique. The three optimized immunoassays exhibited lower limit of quantitation (LLOQ) of 0.474, 0.807, and 0.415?ng/mL, respectively. These preclinical immunoassays showed high sensitivity and specificity. The sandwich enzyme-linked immunosorbent assay (ELISA) could potentially be used for AD diagnosis.
Structural stabilization of the intrinsically disordered SARS-CoV-2 N by binding to RNA sequences engineered from the viral genome fragment Nature Communications 2025 Jul

Abstract

The nucleocapsid N is one of four structural proteins of the coronaviruses. Its essential role in genome encapsidation makes it a critical therapeutic target for COVID-19 and related diseases. However, the inherent disorder of full-length N hampers its structural analysis. Here, we describe a stepwise method using viral-derived RNAs to stabilize SARS-CoV-2 N for EM analysis. We identify pieces of RNA from the SARS-CoV-2 genome that promote the formation of structurally homogeneous N dimers, intermediates of assembly, and filamentous capsid-like structures. Building on these results, we engineer a symmetric RNA to stabilize N protein dimers, the building block of high-order assemblies, for EM studies. We combine domain-specific monoclonal antibodies against N with chemical cross-linking mass spectrometry to validate the spatial arrangement of the N domains within the dimer. Additionally, our cryo-EM analysis reveals novel antigenic sites on the N protein. Our findings provide insights into N protein?s architectural and antigenic principles, which can guide design of pan-coronavirus therapeutics. The authors stabilize the SARS-CoV-2 nucleocapsid (N) dimer assembly using a short RNA and chemical crosslinker for EM analysis, revealing its domain arrangement and antigenic sites to advance understanding and guide pan-coronavirus therapeutic design.